Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR4377)
Name
Rasagiline
Synonyms
rasagiline; 136236-51-6; (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine; Azilect; (R)-N-2-Propynyl-1-indanamine; (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine; 1-Indanamine, N-2-propynyl-, (R)-; (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; UNII-003N66TS6T; TV-1030; Azilect (TN); RAS; CHEMBL887; (1R)-N-propargylindan-1-amine; CHEBI:63620; 003N66TS6T; (R)-Indan-1-yl-prop-2-ynyl-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-; (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; Rasagiline [USAN:INN]; MFCD00866571; HSDB 7699; (1R)-N-prop-2-ynylindan-1-amine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R); TV 1030; PubChem23269; Rasagiline (USAN/INN); SCHEMBL74699; cc-221; MLS006012042; N-propargyl-1-(R)aminoindan; GTPL6641; IND057; SCHEMBL2029054; DTXSID3041112; BDBM10989; HMS3264K12; HMS3715L12; HMS3886N03; Pharmakon1600-01502333; AC-723; ANW-49399; HY-14605A; NSC759639; NSC789038; s5795; ZINC19875504; AKOS006271452; AKOS015837675; AM84542; CCG-213034; DB01367; FS-3130; MCULE-4385913742; NSC 759639; NSC-759639; NSC-789038; SMR002533187; (1R)-N-(prop-2-yn-1-yl)indan-1-amine; AB0035569; DB-001111; A2916; X9941; D08469; S-3541; AB01562963_01; AB01562963_02; Q420685; SR-00000006359; SR-00000006359-3; 1204184-69-9
    Click to Show/Hide
Molecular Type
Small molecule
Disease Parkinson's disease [ICD-11: 8A00] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C12H13N
PubChem CID
3052776
Canonical SMILES
C#CCNC1CCC2=CC=CC=C12
InChI
1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1
InChIKey
RUOKEQAAGRXIBM-GFCCVEGCSA-N
CAS Number
CAS 136236-51-6
ChEBI ID
CHEBI:63620
TTD Drug ID
D06OMW
DrugBank ID
DB01367
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Idebenone      Diplocentrus melici     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression DICER1  Molecule Info 
Pathway MAP
Up-regulation Expression Lin-28A  Molecule Info 
Pathway MAP
Up-regulation Expression LIN28B  Molecule Info 
Pathway MAP
Down-regulation Expression microRNA let-7a-3  Molecule Info 
Pathway MAP
                    Experimental
                    Result(s)
Combination therapy with rasagiline and idebenone produced a synergistic effect that ameliorated RIR injury, restored visual function and provided neuroprotection.
Target and Pathway
Target(s) Monoamine oxidase B (MAO-B)  Molecule Info  [3]
BioCyc Superpathway of tryptophan utilization Click to Show/Hide
2 Tryptophan degradation via tryptamine
3 Dopamine degradation
4 Putrescine degradation III
5 Noradrenaline and adrenaline degradation
KEGG Pathway Glycine, serine and threonine metabolism Click to Show/Hide
2 Arginine and proline metabolism
3 Histidine metabolism
4 Tyrosine metabolism
5 Phenylalanine metabolism
6 Tryptophan metabolism
7 Drug metabolism - cytochrome P450
8 Metabolic pathways
9 Serotonergic synapse
10 Dopaminergic synapse
11 Cocaine addiction
12 Amphetamine addiction
13 Alcoholism
Panther Pathway Adrenaline and noradrenaline biosynthesis Click to Show/Hide
2 5-Hydroxytryptamine degredation
3 Dopamine receptor mediated signaling pathway
Pathway Interaction Database Alpha-synuclein signaling Click to Show/Hide
WikiPathways Tryptophan metabolism Click to Show/Hide
2 Dopamine metabolism
3 Phase 1 - Functionalization of compounds
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6641).
Reference 2 Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. Oncotarget. 2018 Jan 30;9(15):12137-12153.
Reference 3 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China